CADTH has produced a series of reports and tools on the topics of second- and third-line therapy for patients with type 2 diabetes inadequately controlled on metformin.
Summary Reports
Final Reports on Second-Line Therapy
- Optimal Therapy Recommendations for the Prescribing and Use of Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin. Optimal Therapy Report – COMPUS 2010;4(5).
- Second-Line Therapy for Patients With Diabetes Inadequately Controlled on Metformin: A Systematic Review and Cost-Effectiveness Analysis. Optimal Therapy Report – COMPUS 2010;4(2).
- Addendum - Second-line therapy for patients with diabetes when inadequately controlled on metformin — PROJECT PROTOCOL. Optimal Therapy Report - COMPUS 2009;4(1).
- Second-line therapy for patients with diabetes when inadequately controlled on metformin — PROJECT PROTOCOL. Optimal Therapy Report - COMPUS 2009;4(1).
Final Reports on Third-Line Therapy
- CADTH Therapeutic Review Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy (34 pages).
- CADTH Therapeutic Review Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea (205 pages).
- CADTH Therapeutic Review Panel Recommendations Report. Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea (21 pages).
Final Reports on Current Practice and Use
- Current Practice Analysis of Health Care Providers and Patients: Second-line Therapy for Patients With Type 2 Diabetes Inadequately Controlled on Metformin. Optimal Therapy Report - COMPUS 2010;4(4).
- Current Utilization of Second- and Third-Line Therapies in Patients with Type 2 Diabetes. Optimal Therapy Report - COMPUS 2010;4(3).